GLPwatch
GLP-1 receptor agonists and alcohol use disorder: a systematic review.
Alcohol Alcohol · 2025
Last updated 2026-05-28A review of three small clinical trials found that semaglutide reduced alcohol use, dulaglutide lowered alcohol intake in current drinkers, and exenatide did not significantly affect heavy drinking days. The studies included between 48 and 151 participants, but the authors note that larger trials are needed to confirm these findings.
AI summary of the abstract below.
| Journal | Alcohol Alcohol, 2025 |
|---|---|
| Citations | 0 |
| Molecules | — |
| Conditions studied | Alcohol Use Disorder |
Abstract
Observational data on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown a reduction in alcohol use. In this review of three randomized controlled trials (RCTs) (n = 48-151), semaglutide reduced alcohol use, dulaglutide lowered alcohol intake in current drinkers, while exenatide had no significant effect on heavy drinking days. Large RCTs are needed to substantiate the role of GLP-1 RAs in treating alcohol use disorder.
Verbatim abstract via PubMed 41273789 ↗